Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:28 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

ClinicalTrials.gov · NCT05524311 · Registry updated: 2026-04-23

Condition / research focus: Juvenile Dermatomyositis
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: France
Registry dates and results: Start: 2022-11-10. Completion: 2026-01-02 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Baricitinib (drug)
pharmacokinetics study (biological)
dosage of cytokines (biological)
transcriptomic analysis (biological)
Parent version of the Child Health Questionnaire (CHQ) (behavioral)
Childhood Health Assessment Questionnaire (behavioral)
Pregnancy test (biological)

Where the study takes place — 13 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Hôpital Pellegrin
Bordeaux, France
Site recruitment: Not reported
Hôpital Femme Mère Enfant
Bron, France
Site recruitment: Not reported
Hôpital Jeanne de Flandre
Lille, France
Site recruitment: Not reported
Hôpital La Timone
Marseille, France
Site recruitment: Not reported
Hôpital Villeneuce
Montpellier, France
Site recruitment: Not reported
Hôpital Brabois
Nancy, France
Site recruitment: Not reported
Hopital Necker - Enfants malades : unité d'immuno-hématologie et rhumatologie
Paris, France
Site recruitment: Not reported
Hôpital du Kremlin-Bicêtre
Paris, France
Site recruitment: Not reported
Hôpital Necker - Enfants malades : service de dermatologie
Paris, France
Site recruitment: Not reported
Hôpital Robert Debré
Paris, France
Site recruitment: Not reported
Hôpital Trousseau
Paris, France
Site recruitment: Not reported
Hôpital de Hautepierre
Strasbourg, France
Site recruitment: Not reported
Hôpital Purpan
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Enrolling by invitationINTERVENTIONAL

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

ClinicalTrials.gov · NCT07481370 · Registry updated: 2026-04-20

Condition / research focus: Oligospermia; Azoospermia, Nonobstructive; Infertility
Sponsor: University of Nebraska
Countries with listed sites: United States
Registry dates and results: Start: 2026-04-13. Completion: 2027-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

isotretinoin (drug)
Human chorionic gonadotrophin (hCG) (drug)

Where the study takes place — 1 listed sites

University of Nebraska Medical Center
Omaha, Nebraska, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive

ClinicalTrials.gov · NCT07540611 · Registry updated: 2026-04-20

Condition / research focus: APHRODITE Group
Sponsor: Indira IVF Hospital Pvt Ltd
Countries with listed sites: India
Registry dates and results: Start: 2026-07-17. Completion: 2027-07-17 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No intervention (other)
hCG + FSH therapy (other)

Where the study takes place — 8 listed sites

Recruitment
Patna, Bihar, India
Site recruitment: Not reported
Recruitment
Bangalore, Karnataka, India
Site recruitment: Not reported
Recruitment
Bhāndup, Maharashtra, India
Site recruitment: Not reported
Recruitment
Pune, Maharashtra, India
Site recruitment: Not reported
Recruitment
Delhi, National Capital Territory of Delhi, India
Site recruitment: Not reported
Recruitment
Jaipur, Rajasthan, India
Site recruitment: Not reported
Recruitment
Allahābād, Uttar Pradesh, India
Site recruitment: Not reported
Recruitment
Lucknow, Uttar Pradesh, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Enrolling by invitationINTERVENTIONAL

Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups

ClinicalTrials.gov · NCT07523022 · Registry updated: 2026-04-16

Condition / research focus: Male Infertility
Sponsor: Szeged University
Countries with listed sites: Hungary
Registry dates and results: Start: 2024-09-01. Completion: 2026-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recFSH (drug) — also listed as: recombinant FSH
HCG injection (drug) — also listed as: human chorionic gonadotropin, choriogonadotropin alfa
Clomiphene Citrate 50 mg (drug) — also listed as: CC

Where the study takes place — 1 listed sites

Reproductive Medicine Centre, Department of Obstetrics and Gynecology, University of Szeged
Szeged, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start

ClinicalTrials.gov · NCT05444582 · Registry updated: 2026-04-16

Condition / research focus: Contraception
Sponsor: University of Utah
Countries with listed sites: United States
Registry dates and results: Start: 2022-11-07. Completion: 2027-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Levonorgestrel 52 MG Intrauterine System (drug)

Where the study takes place — 8 listed sites

Planned Parenthood Mar Monte
San Jose, California, United States
Site recruitment: Recruiting
Planned Parenthood of the Rocky Mountains
Denver, Colorado, United States
Site recruitment: Recruiting
Planned Parenthood Illinoi
Chicago, Illinois, United States
Site recruitment: Recruiting
Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
Site recruitment: Recruiting
Planned Parenthood North Central States
Saint Paul, Minnesota, United States
Site recruitment: Active, not recruiting
Planned Parenthood Columbia Willamette
Portland, Oregon, United States
Site recruitment: Recruiting
Planned Parenthood Association of Utah
Salt Lake City, Utah, United States
Site recruitment: Recruiting
Planned Parenthood Great Northwest Hawaii, Alaska, Indiana, Kentucky
Seattle, Washington, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

INTEnsity of ovariaN Stimulation and Embryo Quality

ClinicalTrials.gov · NCT04983173 · Registry updated: 2026-04-14

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2021-11-23. Completion: 2026-03-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovarian Stimulation with CC+rFSH (drug)
Ovarian Stimulation with rFSH (drug)

Where the study takes place — 1 listed sites

Salud de la Mujer Dexeus
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

MIcronized PROgesterone in Frozen Embryo Transfer Cycles

ClinicalTrials.gov · NCT05899010 · Registry updated: 2026-03-30

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2023-07-05. Completion: 2028-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vaginal progesterone 600mg daily (drug)
Vaginal progesterone 800mg daily (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

PErsonalized Addition of Recombinant LH in Ovarian Stimulation

ClinicalTrials.gov · NCT04719000 · Registry updated: 2026-03-30

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2021-02-04. Completion: 2027-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rhFSH+rhLH (drug)
rhFSH (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1 / Phase 2TerminatedINTERVENTIONAL

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

ClinicalTrials.gov · NCT05123040 · Registry updated: 2026-03-24

Condition / research focus: Acute-graft-versus-host Disease
Sponsor: Masonic Cancer Center, University of Minnesota
Countries with listed sites: United States
Registry dates and results: Start: 2023-06-05. Completion: 2026-02-27 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ruxolitinib 10 MG Oral Tablet (drug)
hCG (drug) — also listed as: Pregnyl
Corticosteroids (drug) — also listed as: Prednisone, IV methylprednisolone

Where the study takes place — 1 listed sites

Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule

ClinicalTrials.gov · NCT03785574 · Registry updated: 2026-03-16

Condition / research focus: Hydatidiform Mole; Gestational Trophoblastic Neoplasia
Sponsor: Women's Hospital School Of Medicine Zhejiang University
Countries with listed sites: China
Registry dates and results: Start: 2018-12-24. Completion: 2030-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follow up (other) — also listed as: not chemotherapy immediately
chemotherapy (drug) — also listed as: mtx for low risk

Where the study takes place — 1 listed sites

Weiguo Lv
Hangzhou, Zhejiang, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

ClinicalTrials.gov · NCT07043322 · Registry updated: 2026-03-13

Condition / research focus: Gynecologic Disease
Sponsor: Tanta University
Countries with listed sites: Egypt
Registry dates and results: Start: 2025-06-30. Completion: 2026-11-20 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Coasting (procedure)
Cabergoline (drug)

Where the study takes place — 1 listed sites

Mostafa Bahaa
Damietta, New Damietta, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity

ClinicalTrials.gov · NCT07463508 · Registry updated: 2026-03-11

Condition / research focus: Testicular Germ Cell Cancer
Sponsor: University Hospital, Clermont-Ferrand
Countries with listed sites: France
Registry dates and results: Start: 2026-01-01. Completion: 2029-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

blood sampling (biological)
Tissue sampling (procedure)

Where the study takes place — 1 listed sites

CHU Clermont-Ferrand
Clermont-Ferrand, France
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Next Generation Personalized Neuroblastoma Therapy

ClinicalTrials.gov · NCT02780128 · Registry updated: 2026-03-10

Condition / research focus: Neuroblastoma; Cancer
Sponsor: Yael P Mosse
Countries with listed sites: United States
Registry dates and results: Start: 2016-07. Completion: 2022-08 (may be estimated). No results posted in this registry response.

Products and interventions (13)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Biopsy (procedure) — also listed as: Genetic Sequencing
Next Generation Sequencing (genetic) — also listed as: Molecular Profiling, Genetic Sequencing
Tumor Scans (procedure)
Bone marrow Tests (procedure) — also listed as: Bone marrow aspiration
Physical Exam (other)
Eye Exam (other) — also listed as: Ophthalmic Exam
Labs (other) — also listed as: Blood tests
Pregnancy Test (other)
Interviews (behavioral)
ECG (other) — also listed as: EKG, Electrocardiogram
Echocardiogram (other) — also listed as: ECHO
Ribociclib (drug) — also listed as: LEE011
Ceritinib (drug) — also listed as: LDK378

Where the study takes place — 1 listed sites

The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients

ClinicalTrials.gov · NCT07450300 · Registry updated: 2026-03-04

Condition / research focus: Infertility, Female
Sponsor: Clinique Mathilde
Countries with listed sites: France
Registry dates and results: Start: 2022-11-01. Completion: 2026-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Modified natural cycle (procedure)
Substitued cycle (procedure)
Hormonal replacement therapy (procedure)

Where the study takes place — 1 listed sites

Clinique Mathilde
Rouen, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

ClinicalTrials.gov · NCT04886726 · Registry updated: 2026-02-24

Condition / research focus: Graft Versus Host Disease
Sponsor: Henry Ford Health System
Countries with listed sites: United States
Registry dates and results: Start: 2021-12-23. Completion: 2028-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

uhCG/EGF (drug)

Where the study takes place — 1 listed sites

Henry Ford Hospital
Detroit, Michigan, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer

ClinicalTrials.gov · NCT06307184 · Registry updated: 2026-02-23

Condition / research focus: Frozen Embryo Transfer
Sponsor: Instituto Valenciano de Infertilidade de Lisboa
Countries with listed sites: Portugal
Registry dates and results: Start: 2024-02-23. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Natural proliferative phase frozen embryo transfer (procedure)

Where the study takes place — 1 listed sites

Instituto Valenciano de Infertilidade
Lisbon, Portugal
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

A Prospective Multicenter Observational Real-world Study of Retained Products of Conception

ClinicalTrials.gov · NCT07421895 · Registry updated: 2026-02-19

Condition / research focus: Retained Products of Conception; RPOC
Sponsor: The Third Xiangya Hospital of Central South University
Countries with listed sites: China
Registry dates and results: Start: 2022-06-01. Completion: 2032-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Uterine curettage (procedure)
Expectant care (drug)

Where the study takes place — 1 listed sites

The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

MAIT Cells in Hidradenitis Suppurativa

ClinicalTrials.gov · NCT07388446 · Registry updated: 2026-02-05

Condition / research focus: Hidradenitis Suppurativa (HS)
Sponsor: Hospices Civils de Lyon
Countries with listed sites: France
Registry dates and results: Start: 2026-02-01. Completion: 2027-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Collect lesional biopsies (other)
Collect score from Bristol stool scale (other)

Where the study takes place — 1 listed sites

Hôpital Edouard Herriot - Dermatologie - CLIMA Pav R
Lyon, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

ClinicalTrials.gov · NCT07079930 · Registry updated: 2026-02-05

Condition / research focus: Healthy Volunteers
Sponsor: Hadassah Medical Organization
Countries with listed sites: Israel
Registry dates and results: Start: 2025-12-11. Completion: 2027-02 (may be estimated). No results posted in this registry response.

Products and interventions (21)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Psilocybin and D-Serine (drug)
Physical Examination (diagnostic_test)
Vital signs (diagnostic_test)
ECG test (diagnostic_test)
Comprehensive Blood Panel (diagnostic_test) — also listed as: SMAC-20
Complete Blood Count (diagnostic_test) — also listed as: CBC
Urinalysis (diagnostic_test)
Urine Toxicology Screen (diagnostic_test)
A pregnancy Urine test (diagnostic_test)
Electroencephalogram (diagnostic_test) — also listed as: EEG
Plasma Amino Acid Levels (diagnostic_test)
Plasma Inflammation Markers (diagnostic_test)
Plasma Brain-Derived Neurotrophic Facto (diagnostic_test) — also listed as: Plasma BDNF
Mini International Neuropsychiatric Interview (other) — also listed as: MINI
Family Psychiatric History Assessment (other) — also listed as: FPHA
Beck Depression Inventory (other) — also listed as: BDI
State-Trait Anxiety Inventory (other) — also listed as: STAI
Profile of Mood States (behavioral) — also listed as: POMS
Subjective Units of Distress Scale (behavioral) — also listed as: SUDS
Five-Dimensional Altered States of Consciousness questionnaire (other) — also listed as: 5D-ASC
Integration (behavioral)

Where the study takes place — 1 listed sites

Hadassah Medical Organization, Jerusalem, Israel
Jerusalem, Israel
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

ClinicalTrials.gov · NCT06440850 · Registry updated: 2026-02-02

Condition / research focus: Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma
Sponsor: City of Hope Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-15. Completion: 2026-11-22 (may be estimated). No results posted in this registry response.

Products and interventions (11)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Biospecimen Collection (procedure) — also listed as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Cobimetinib (drug) — also listed as: Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518
Computed Tomography (procedure) — also listed as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
Diagnostic Imaging (procedure) — also listed as: Medical Imaging
I-131 Uptake Test (procedure) — also listed as: I 131 Uptake, I-131 Uptake and Scan, Radioactive Iodine Uptake
Iodine I-131 (radiation) — also listed as: 131-Iodine, Bound Iodide I-131, I 131, I-131, Iodide I-131, Iodide, I-131, Iodine 131, Iodine-131, Iodotope, Iodotrope
Magnetic Resonance Imaging (procedure) — also listed as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Positron Emission Tomography (procedure) — also listed as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Recombinant Thyrotropin Alfa (biological) — also listed as: Recombinant Thyrotropin Alpha, Recombinant TSH Alpha, Thyrogen, Thyroid Stimulating Hormone Alpha, Thyrotropin Alfa, TSH-alpha
Ultrasound Imaging (procedure) — also listed as: 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Vemurafenib (drug) — also listed as: BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf

Where the study takes place — 1 listed sites

City of Hope Medical Center
Duarte, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:28 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

ClinicalTrials.gov · NCT05524311 · Registry updated: 2026-04-23

Condition / research focus: Juvenile Dermatomyositis
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: France
Registry dates and results: Start: 2022-11-10. Completion: 2026-01-02 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Baricitinib (drug)
pharmacokinetics study (biological)
dosage of cytokines (biological)
transcriptomic analysis (biological)
Parent version of the Child Health Questionnaire (CHQ) (behavioral)
Childhood Health Assessment Questionnaire (behavioral)
Pregnancy test (biological)

Where the study takes place — 13 listed sites

Hôpital Pellegrin
Bordeaux, France
Site recruitment: Not reported
Hôpital Femme Mère Enfant
Bron, France
Site recruitment: Not reported
Hôpital Jeanne de Flandre
Lille, France
Site recruitment: Not reported
Hôpital La Timone
Marseille, France
Site recruitment: Not reported
Hôpital Villeneuce
Montpellier, France
Site recruitment: Not reported
Hôpital Brabois
Nancy, France
Site recruitment: Not reported
Hopital Necker - Enfants malades : unité d'immuno-hématologie et rhumatologie
Paris, France
Site recruitment: Not reported
Hôpital du Kremlin-Bicêtre
Paris, France
Site recruitment: Not reported
Hôpital Necker - Enfants malades : service de dermatologie
Paris, France
Site recruitment: Not reported
Hôpital Robert Debré
Paris, France
Site recruitment: Not reported
Hôpital Trousseau
Paris, France
Site recruitment: Not reported
Hôpital de Hautepierre
Strasbourg, France
Site recruitment: Not reported
Hôpital Purpan
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Enrolling by invitationINTERVENTIONAL

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

ClinicalTrials.gov · NCT07481370 · Registry updated: 2026-04-20

Condition / research focus: Oligospermia; Azoospermia, Nonobstructive; Infertility
Sponsor: University of Nebraska
Countries with listed sites: United States
Registry dates and results: Start: 2026-04-13. Completion: 2027-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

isotretinoin (drug)
Human chorionic gonadotrophin (hCG) (drug)

Where the study takes place — 1 listed sites

University of Nebraska Medical Center
Omaha, Nebraska, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive

ClinicalTrials.gov · NCT07540611 · Registry updated: 2026-04-20

Condition / research focus: APHRODITE Group
Sponsor: Indira IVF Hospital Pvt Ltd
Countries with listed sites: India
Registry dates and results: Start: 2026-07-17. Completion: 2027-07-17 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No intervention (other)
hCG + FSH therapy (other)

Where the study takes place — 8 listed sites

Recruitment
Patna, Bihar, India
Site recruitment: Not reported
Recruitment
Bangalore, Karnataka, India
Site recruitment: Not reported
Recruitment
Bhāndup, Maharashtra, India
Site recruitment: Not reported
Recruitment
Pune, Maharashtra, India
Site recruitment: Not reported
Recruitment
Delhi, National Capital Territory of Delhi, India
Site recruitment: Not reported
Recruitment
Jaipur, Rajasthan, India
Site recruitment: Not reported
Recruitment
Allahābād, Uttar Pradesh, India
Site recruitment: Not reported
Recruitment
Lucknow, Uttar Pradesh, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Enrolling by invitationINTERVENTIONAL

Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups

ClinicalTrials.gov · NCT07523022 · Registry updated: 2026-04-16

Condition / research focus: Male Infertility
Sponsor: Szeged University
Countries with listed sites: Hungary
Registry dates and results: Start: 2024-09-01. Completion: 2026-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recFSH (drug) — also listed as: recombinant FSH
HCG injection (drug) — also listed as: human chorionic gonadotropin, choriogonadotropin alfa
Clomiphene Citrate 50 mg (drug) — also listed as: CC

Where the study takes place — 1 listed sites

Reproductive Medicine Centre, Department of Obstetrics and Gynecology, University of Szeged
Szeged, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start

ClinicalTrials.gov · NCT05444582 · Registry updated: 2026-04-16

Condition / research focus: Contraception
Sponsor: University of Utah
Countries with listed sites: United States
Registry dates and results: Start: 2022-11-07. Completion: 2027-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Levonorgestrel 52 MG Intrauterine System (drug)

Where the study takes place — 8 listed sites

Planned Parenthood Mar Monte
San Jose, California, United States
Site recruitment: Recruiting
Planned Parenthood of the Rocky Mountains
Denver, Colorado, United States
Site recruitment: Recruiting
Planned Parenthood Illinoi
Chicago, Illinois, United States
Site recruitment: Recruiting
Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
Site recruitment: Recruiting
Planned Parenthood North Central States
Saint Paul, Minnesota, United States
Site recruitment: Active, not recruiting
Planned Parenthood Columbia Willamette
Portland, Oregon, United States
Site recruitment: Recruiting
Planned Parenthood Association of Utah
Salt Lake City, Utah, United States
Site recruitment: Recruiting
Planned Parenthood Great Northwest Hawaii, Alaska, Indiana, Kentucky
Seattle, Washington, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

INTEnsity of ovariaN Stimulation and Embryo Quality

ClinicalTrials.gov · NCT04983173 · Registry updated: 2026-04-14

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2021-11-23. Completion: 2026-03-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovarian Stimulation with CC+rFSH (drug)
Ovarian Stimulation with rFSH (drug)

Where the study takes place — 1 listed sites

Salud de la Mujer Dexeus
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

MIcronized PROgesterone in Frozen Embryo Transfer Cycles

ClinicalTrials.gov · NCT05899010 · Registry updated: 2026-03-30

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2023-07-05. Completion: 2028-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vaginal progesterone 600mg daily (drug)
Vaginal progesterone 800mg daily (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

PErsonalized Addition of Recombinant LH in Ovarian Stimulation

ClinicalTrials.gov · NCT04719000 · Registry updated: 2026-03-30

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2021-02-04. Completion: 2027-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

rhFSH+rhLH (drug)
rhFSH (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1 / Phase 2TerminatedINTERVENTIONAL

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

ClinicalTrials.gov · NCT05123040 · Registry updated: 2026-03-24

Condition / research focus: Acute-graft-versus-host Disease
Sponsor: Masonic Cancer Center, University of Minnesota
Countries with listed sites: United States
Registry dates and results: Start: 2023-06-05. Completion: 2026-02-27 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ruxolitinib 10 MG Oral Tablet (drug)
hCG (drug) — also listed as: Pregnyl
Corticosteroids (drug) — also listed as: Prednisone, IV methylprednisolone

Where the study takes place — 1 listed sites

Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule

ClinicalTrials.gov · NCT03785574 · Registry updated: 2026-03-16

Condition / research focus: Hydatidiform Mole; Gestational Trophoblastic Neoplasia
Sponsor: Women's Hospital School Of Medicine Zhejiang University
Countries with listed sites: China
Registry dates and results: Start: 2018-12-24. Completion: 2030-09-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follow up (other) — also listed as: not chemotherapy immediately
chemotherapy (drug) — also listed as: mtx for low risk

Where the study takes place — 1 listed sites

Weiguo Lv
Hangzhou, Zhejiang, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

ClinicalTrials.gov · NCT07043322 · Registry updated: 2026-03-13

Condition / research focus: Gynecologic Disease
Sponsor: Tanta University
Countries with listed sites: Egypt
Registry dates and results: Start: 2025-06-30. Completion: 2026-11-20 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Coasting (procedure)
Cabergoline (drug)

Where the study takes place — 1 listed sites

Mostafa Bahaa
Damietta, New Damietta, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity

ClinicalTrials.gov · NCT07463508 · Registry updated: 2026-03-11

Condition / research focus: Testicular Germ Cell Cancer
Sponsor: University Hospital, Clermont-Ferrand
Countries with listed sites: France
Registry dates and results: Start: 2026-01-01. Completion: 2029-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

blood sampling (biological)
Tissue sampling (procedure)

Where the study takes place — 1 listed sites

CHU Clermont-Ferrand
Clermont-Ferrand, France
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Next Generation Personalized Neuroblastoma Therapy

ClinicalTrials.gov · NCT02780128 · Registry updated: 2026-03-10

Condition / research focus: Neuroblastoma; Cancer
Sponsor: Yael P Mosse
Countries with listed sites: United States
Registry dates and results: Start: 2016-07. Completion: 2022-08 (may be estimated). No results posted in this registry response.

Products and interventions (13)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Biopsy (procedure) — also listed as: Genetic Sequencing
Next Generation Sequencing (genetic) — also listed as: Molecular Profiling, Genetic Sequencing
Tumor Scans (procedure)
Bone marrow Tests (procedure) — also listed as: Bone marrow aspiration
Physical Exam (other)
Eye Exam (other) — also listed as: Ophthalmic Exam
Labs (other) — also listed as: Blood tests
Pregnancy Test (other)
Interviews (behavioral)
ECG (other) — also listed as: EKG, Electrocardiogram
Echocardiogram (other) — also listed as: ECHO
Ribociclib (drug) — also listed as: LEE011
Ceritinib (drug) — also listed as: LDK378

Where the study takes place — 1 listed sites

The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients

ClinicalTrials.gov · NCT07450300 · Registry updated: 2026-03-04

Condition / research focus: Infertility, Female
Sponsor: Clinique Mathilde
Countries with listed sites: France
Registry dates and results: Start: 2022-11-01. Completion: 2026-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Modified natural cycle (procedure)
Substitued cycle (procedure)
Hormonal replacement therapy (procedure)

Where the study takes place — 1 listed sites

Clinique Mathilde
Rouen, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

ClinicalTrials.gov · NCT04886726 · Registry updated: 2026-02-24

Condition / research focus: Graft Versus Host Disease
Sponsor: Henry Ford Health System
Countries with listed sites: United States
Registry dates and results: Start: 2021-12-23. Completion: 2028-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

uhCG/EGF (drug)

Where the study takes place — 1 listed sites

Henry Ford Hospital
Detroit, Michigan, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer

ClinicalTrials.gov · NCT06307184 · Registry updated: 2026-02-23

Condition / research focus: Frozen Embryo Transfer
Sponsor: Instituto Valenciano de Infertilidade de Lisboa
Countries with listed sites: Portugal
Registry dates and results: Start: 2024-02-23. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Natural proliferative phase frozen embryo transfer (procedure)

Where the study takes place — 1 listed sites

Instituto Valenciano de Infertilidade
Lisbon, Portugal
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

A Prospective Multicenter Observational Real-world Study of Retained Products of Conception

ClinicalTrials.gov · NCT07421895 · Registry updated: 2026-02-19

Condition / research focus: Retained Products of Conception; RPOC
Sponsor: The Third Xiangya Hospital of Central South University
Countries with listed sites: China
Registry dates and results: Start: 2022-06-01. Completion: 2032-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Uterine curettage (procedure)
Expectant care (drug)

Where the study takes place — 1 listed sites

The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

MAIT Cells in Hidradenitis Suppurativa

ClinicalTrials.gov · NCT07388446 · Registry updated: 2026-02-05

Condition / research focus: Hidradenitis Suppurativa (HS)
Sponsor: Hospices Civils de Lyon
Countries with listed sites: France
Registry dates and results: Start: 2026-02-01. Completion: 2027-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Collect lesional biopsies (other)
Collect score from Bristol stool scale (other)

Where the study takes place — 1 listed sites

Hôpital Edouard Herriot - Dermatologie - CLIMA Pav R
Lyon, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

ClinicalTrials.gov · NCT07079930 · Registry updated: 2026-02-05

Condition / research focus: Healthy Volunteers
Sponsor: Hadassah Medical Organization
Countries with listed sites: Israel
Registry dates and results: Start: 2025-12-11. Completion: 2027-02 (may be estimated). No results posted in this registry response.

Products and interventions (21)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Psilocybin and D-Serine (drug)
Physical Examination (diagnostic_test)
Vital signs (diagnostic_test)
ECG test (diagnostic_test)
Comprehensive Blood Panel (diagnostic_test) — also listed as: SMAC-20
Complete Blood Count (diagnostic_test) — also listed as: CBC
Urinalysis (diagnostic_test)
Urine Toxicology Screen (diagnostic_test)
A pregnancy Urine test (diagnostic_test)
Electroencephalogram (diagnostic_test) — also listed as: EEG
Plasma Amino Acid Levels (diagnostic_test)
Plasma Inflammation Markers (diagnostic_test)
Plasma Brain-Derived Neurotrophic Facto (diagnostic_test) — also listed as: Plasma BDNF
Mini International Neuropsychiatric Interview (other) — also listed as: MINI
Family Psychiatric History Assessment (other) — also listed as: FPHA
Beck Depression Inventory (other) — also listed as: BDI
State-Trait Anxiety Inventory (other) — also listed as: STAI
Profile of Mood States (behavioral) — also listed as: POMS
Subjective Units of Distress Scale (behavioral) — also listed as: SUDS
Five-Dimensional Altered States of Consciousness questionnaire (other) — also listed as: 5D-ASC
Integration (behavioral)

Where the study takes place — 1 listed sites

Hadassah Medical Organization, Jerusalem, Israel
Jerusalem, Israel
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

ClinicalTrials.gov · NCT06440850 · Registry updated: 2026-02-02

Condition / research focus: Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma
Sponsor: City of Hope Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-15. Completion: 2026-11-22 (may be estimated). No results posted in this registry response.

Products and interventions (11)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Biospecimen Collection (procedure) — also listed as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Cobimetinib (drug) — also listed as: Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518
Computed Tomography (procedure) — also listed as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
Diagnostic Imaging (procedure) — also listed as: Medical Imaging
I-131 Uptake Test (procedure) — also listed as: I 131 Uptake, I-131 Uptake and Scan, Radioactive Iodine Uptake
Iodine I-131 (radiation) — also listed as: 131-Iodine, Bound Iodide I-131, I 131, I-131, Iodide I-131, Iodide, I-131, Iodine 131, Iodine-131, Iodotope, Iodotrope
Magnetic Resonance Imaging (procedure) — also listed as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Positron Emission Tomography (procedure) — also listed as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Recombinant Thyrotropin Alfa (biological) — also listed as: Recombinant Thyrotropin Alpha, Recombinant TSH Alpha, Thyrogen, Thyroid Stimulating Hormone Alpha, Thyrotropin Alfa, TSH-alpha
Ultrasound Imaging (procedure) — also listed as: 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Vemurafenib (drug) — also listed as: BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf

Where the study takes place — 1 listed sites

City of Hope Medical Center
Duarte, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →